| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6122718 | Journal of Infection | 2015 | 12 Pages |
Abstract
This study provides a proof-of-concept for generating bactericidal antibodies against FetA after OMV vaccination in humans. Prevalence-based choice of PorA and FetA types can be used to formulate a vaccine for broad protection against MenB disease.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
L. Marsay, C. Dold, C.A. Green, C.S. Rollier, G. Norheim, M. Sadarangani, M. Shanyinde, C. Brehony, A.J. Thompson, H. Sanders, H. Chan, K. Haworth, J.P. Derrick, I.M. Feavers, M.C. Maiden, A.J. Pollard,